

DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

BALANCE SHEET

(All amounts in Rs. unless otherwise stated)

		As at	
	Note	March 31, 2020	March 31, 2019
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	3	2,000,000	2,000,000
Corpus Fund	4	100,000	100,000
Reserves and surplus	5	207,540,288	121,873
		209,640,288	2,221,873
Non-current liabilities			
Other long-term liability	6	877,796	-
Long-term provisions	7	533,166	-
		1,410,962	-
Current liabilities			
Trade payables	8		
- Total outstanding dues of micro and small enterprises		51,840	-
- Total outstanding dues of creditors other than micro and small enterprises		34,146,166	-
Other current liabilities	9	3,069,621	-
Short-term provisions	10	2,245,163	-
		39,512,790	-
TOTAL		250,564,040	2,221,873
ASSETS			
Non-current assets			
Property, plant and equipment -Tangible assets	11	7,079,335	-
Long-term loans and advances	12	14,683,284	3,000
		21,762,619	3,000
Current assets			
Trade receivables	13	3,633,619	-
Cash and bank balances	14	223,378,892	2,218,873
Short-term loans and advances	15	1,765,270	-
Other current assets	16	23,640	-
		228,801,421	2,218,873
TOTAL		250,564,040	2,221,873

The accompanying notes are an integral part of these financial statements.

This is the Balance Sheet referred to in our report of even date.


For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Madhavi Kalva
Partner
Membership Number: 213550

Place: Bengaluru
Date: September 10, 2020

For and on behalf of the Board of Directors




Dr. Latha Jagannathan
Director
DIN: 00176248

Place: Bengaluru
Date: September 10, 2020



Prabhaskar K N
Director
DIN: 01499577

Place: Bengaluru
Date: September 10, 2020



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

STATEMENT OF INCOME AND EXPENDITURE
(All amounts in Rs. unless otherwise stated)

	Note	Year ended March 31, 2020	Year ended March 31, 2019
Income			
Donations and Grants	19	314,429,147	502,000
Fees from activities		12,120,911	-
Other income	20	23,640	-
Total (I)		326,573,698	502,000
Expenses			
Employee benefits expense	21	29,883,120	-
Depreciation and amortisation expense	11	1,076,107	-
Other expenses	22	35,299,570	271,946
Donor and transplantation expense		52,633,316	-
Total (II)		118,892,113	271,946
Surplus for the period (I)-(II)		207,681,585	230,054
Tax expense			
- Current tax		263,170	-
		263,170	-
Surplus for the year		207,418,415	230,054
Earnings per equity share - Basic	26	1,037	1
[Nominal value per share: Rs. 10 (2019: Rs. 10)]			

The accompanying notes are an integral part of these financial statements.

This is the Income and Expenditure referred to in our report of even date.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016

Madhavi Kalva

Madhavi Kalva
Partner
Membership Number: 213550

Place: Bengaluru
Date: September 10, 2020

For and on behalf of the Board of Directors

Dr. Latha Jagannathan


Dr. Latha Jagannathan
Director
DIN: 00176248

Place: Bengaluru
Date: September 10, 2020

Prabhashankar K N

Prabhashankar K N
Director
DIN: 01499577

Place: Bengaluru
Date: September 10, 2020



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

CASH FLOW STATEMENT

(All amounts in Rs. unless otherwise stated)

	Year ended March 31, 2020	Year ended March 31, 2019
Surplus before tax	207,681,585	230,054
Non-cash adjustment to reconcile surplus before tax to net cash flows		
Depreciation and amortisation expense	1,076,107	-
Interest income	(23,640)	-
Unrealised foreign exchange loss (net)	4,097,943	-
Operating profit before working capital changes	212,831,995	230,054
Changes in working capital:		
Increase/ (decrease) in trade payables	30,023,672	-
Increase / (decrease) in long-term provisions	533,166	-
Increase / (decrease) in short-term provisions	1,981,993	-
Increase/(decrease) in other long term liabilities	877,796	-
Increase/(decrease) in other current liabilities	3,069,621	-
(Increase)/ decrease in trade receivables	(3,557,228)	-
(Increase)/decrease in long term loans and advances	(14,680,284)	-
(Increase)/decrease in short term loans and advances	(1,765,270)	-
Cash generated from operations	229,315,461	230,054
Taxes paid (net of refunds)	-	-
Net cash generated from operating activities	(A) 229,315,461	230,054
Cash flow from investing activities		
Purchase of Property, plant and equipment - Tangible assets	(8,155,442)	-
Net cash used in investing activities	(B) (8,155,442)	-
Cash flow from financing activities		
Proceeds from issues of equity shares	-	1,900,000
Net cash generated from financing activities	(C) -	1,900,000
Net increase/ (decrease) in cash and cash equivalents	(A+B+C) 221,160,019	2,130,054
Cash and cash equivalents at the beginning of the year (refer Note 14)	2,218,873	88,819
Cash and cash equivalents at the end of the year (refer Note 14)	223,378,892	2,218,873

This is the Cash Flow Statement referred to in our report of even date.


For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Madhavi Kalva
Partner
Membership Number: 213550

Place: Bengaluru
Date: September 10, 2020

For and on behalf of the Board of Directors



Dr. Latha Jagannathan
Director
DIN: 00176248

Prabhashankar K N
Director
DIN: 01499577

Place: Bengaluru
Date: September 10, 2020

Place: Bengaluru
Date: September 10, 2020



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS

1 General information:

DKMS BMST Foundation India (CIN: U74900KA2015NPL082065) ("the Company") is a private limited company, incorporated on August 6, 2015 under Section 8 of the Companies Act, 2013, with the primary objective to help and support people suffering from blood cancer and other diseases in particular to those for which stem cell transplant is an appropriate treatment and to set up stem cell donor center in India. The name of the company was changed from BMST Stem Cell Donor Registry Foundation India to DKMS BMST Foundation India with effect from August 13, 2018. The Company has its registered office in Bengaluru.

2 Summary of significant accounting policies

(i) Basis of Preparation

These financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on accrual basis. These financial statements have been prepared to comply in all material aspects with the applicable Accounting Standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended), specified under section 133 and other relevant provisions of the Companies Act, 2013 ("the Act").

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division I) to the Companies Act, 2013. Based on the nature of services and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current – non-current classification of assets and liabilities.

(ii) Use of estimates


The preparation of financial statements in conformity with generally accepted accounting principles in India requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities as on the date of the financial statements and the reported amounts of income and expenses during the reported period. Actual results could differ from those estimates. Any revision to accounting estimates is recognised prospectively in current and future periods.

(iii) Property, plant and equipment - Tangible assets

Tangible assets are stated at their original cost of acquisition and subsequent improvements including taxes, duties, freight and other incidental expenses related to acquisition and installation of the assets concerned thereto (only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance), net of accumulated depreciation and accumulated impairment losses, if any. Tangible assets are capitalised on the date on which they are ready to be put to use.

Depreciation is provided on a pro-rata basis on the straight line method over the estimated useful lives of the assets, based on technical evaluation done by management taking into account the nature of the assets, their estimated period of use and the operating conditions. The depreciation charge for each period is recognised in the Statement of Income and Expenditure. The useful life, residual value and the depreciation method are reviewed atleast at each financial year end. If the expectations differ from previous estimates, the changes are accounted for prospectively as a change in accounting estimate. The estimates of useful lives of tangible assets are as follows :

Asset	Useful Life as prescribed under the Act (Years)	Management estimate of useful life (Years)
Computer equipment	3	3
Office equipment	5	5
Leasehold improvements	NA	7
Furniture and fixtures	10	10



NOTES TO THE FINANCIAL STATEMENTS

(iv) Impairment of assets

Assessment is done at each Balance Sheet date as to whether there is any indication that an asset (tangible and intangible) may be impaired. For the purpose of assessing impairment, the smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets, is considered as a cash generating unit. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Assets whose carrying value exceeds their recoverable amount are written down to the recoverable amount. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Assessment is also done at each Balance Sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exists or may have decreased. An impairment loss is reversed to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined if no impairment loss had previously been recognised.

(v) Foreign currency transactions

Initial recognition:

On initial recognition, all foreign currency transactions are recorded by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Subsequent recognition:

As at the reporting date, non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction.

All monetary assets and liabilities in foreign currency are restated at the end of the accounting period. Exchange differences on restatement of all monetary items are recognised in Statement of Income and Expenditure.

(vi) Income Recognition:

Grants and donations received:

Grants and donations received for which there are no stipulations as to use are recognised in the Statement of Income and Expenditure as income in the period of receipt.

Fees from activities

Services rendered with respect to stem cell transplantation are accounted on an accrual basis.

(vii) Interest income:

Interest income on fixed deposits is recognised on a time proportion basis over the term of the fixed deposits.

(viii) Earnings Per Share

Basic earnings per share is calculated by dividing surplus/ (deficit) for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Earnings considered in ascertaining the Company's earnings per share is the surplus for the period after deducting preference dividends and any attributable tax thereto for the period. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the surplus/ (deficit) for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares.



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS

(ix) Retirement and Other Benefits

(a) Defined Contribution Plans:

Contribution towards provident fund for employees is made to the regulatory authorities, where the Company has no further obligations. Such benefits are classified as Defined Contribution Schemes as the Company does not carry any further obligations, apart from the contributions made on a monthly basis. The Company's contributions thereto are charged to the Statement of Income & Expenditure every year.

(b) Defined Benefit Plans:

The Company provides for gratuity, a defined benefit plan (the "Gratuity Plan") covering eligible employees in accordance with the Payment of Gratuity Act, 1972 and amendments thereto. The Company's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. Actuarial losses/ gains are recognised in the Statement of Income & Expenditure in the year in which they arise.

(c) Other long-term employee benefits:

Liability towards leave entitlements and compensated absences are recognised using the Projected Unit Credit method based on actuarial valuation at each Balance sheet date. Actuarial gains/ losses are recognised in the Statement of Income & Expenditure in the year in which they arise.

(d) Short term employee benefits:

Liability towards compensated absences, performance incentives etc. are recognised during the period when the employee renders the services.

(x) Provisions and Contingent Liabilities

Provisions are recognised when there is a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance sheet date and are not discounted to its present value.

Contingent Liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

(xi) Segment Reporting


The accounting policies adopted for segment reporting are in conformity with the accounting policies adopted for the Company. Income and expenses have been identified to segments on the basis of their relationship to the operating activities of the segment.

(xii) Leases

As a lessee: Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating lease. Payments made under operating leases are charged to the Statement of Income & Expenditure on a straight – line basis over the period of the lease.

(xiii) Cash and Cash Equivalents

In the cash flow statement, cash and cash equivalents include cash in hand, demand deposits with banks, other short-term highly liquid investments with original maturities of three months or less.



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS

(All amounts in Rs. unless otherwise stated)

3 Share capital

Authorised:

1,000,000 (March 31, 2019: 1,000,000) equity shares of Rs.10 each

As at
March 31,
2020
March 31,
2019

10,000,000 10,000,000

Issued, subscribed and paid-up:

200,000 (March 31, 2019: 200,000) equity shares of Rs.10 each fully paid-up

2,000,000 2,000,000

2,000,000 2,000,000

(a) Reconciliation of number of equity shares

Balance as at the beginning of the year

Add: Shares issued during the year

Balance as at the end of the year

March 31, 2020		March 31, 2019	
No. of shares	Amount	No. of shares	Amount
200,000	2,000,000	10,000	100,000
-	-	190,000	1,900,000
200,000	2,000,000	200,000	2,000,000

(b) Rights, preferences and restrictions attached to equity shares

Equity shares: The Company has one class of equity shares having a par value of Rs. 10 each. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of any preferential amounts, in proportion to their shareholding.

(c) Shares held by holding company and subsidiary of holding company:

DKMS Gemeinnutzige GmbH, Germany, holding company

March 31, 2020		March 31, 2019	
No. of shares	Amount	No. of shares	Amount
150,000	1,500,000	150,000	1,500,000
150,000	1,500,000	150,000	1,500,000

(d) Details of shares held by shareholders holding more than 5% of the aggregate shares in the Company

Bangalore Medical Services Trust

DKMS Gemeinnutzige GmbH, Germany, holding company

March 31, 2020		March 31, 2019	
No. of shares	%	No. of shares	%
50,000	25.00%	50,000	500.00%
150,000	75.00%	150,000	1500.00%

(e) There are no shares reserved for issue under options.

(f) There are no shares allotted as fully paid-up by way of bonus shares, shares allotted as fully paid-up pursuant to contract without payment being received in cash or shares bought back during 5 years immediately preceding March 31, 2020.

(g) There are no securities convertible into equity shares as on March 31, 2020.

(h) There are no shares which have been forfeited as at March 31, 2020.




DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS

(All amounts in Rs. unless otherwise stated)

	As at	
	March 31, 2020	March 31, 2019
4 Corpus Fund		
Opening balance	100,000	100,000
Add: Contributions received towards Corpus Fund	-	-
Closing balance	100,000	100,000
5 Reserve & Surplus		
Surplus in the Statement of Income and Expenditure		
Balance at the beginning of the year	121,873	(108,181)
Add: Surplus for the year	207,418,415	230,054
Balance at the end of the year	207,540,288	121,873
6 Other long term liabilities		
Deferred lease payments	877,796	-
	877,796	-
7 Long-term provisions		
Provision for employee benefits		
Gratuity (refer Note 21)	533,166	-
	533,166	-
8 Trade payables		
Total outstanding dues of micro enterprises and small enterprises (refer Note 29)	51,840	-
Total outstanding dues of creditors other than micro enterprises and small enterprises (refer Note 27)	34,146,166	-
	34,198,006	-
9 Other current liabilities		
Employee benefits payable	121,786	-
Statutory dues including provident fund and tax deducted at source	2,947,835	-
	3,069,621	-
10 Short-term provisions		
Provision for Income Tax (refer Note 30)	263,170	-
Provision for employee benefits		
Gratuity (refer Note 21)	2,313	-
Compensated absences*	1,979,680	-
	2,245,163	-

*Provision for Compensated absences is disclosed as current since the Company does not have an unconditional right to defer settlement for any of these obligations. The excepted payment for the next 12 months is Rs. 276,746.




DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)
NOTES TO THE FINANCIAL STATEMENTS
(All amounts in Rs. unless otherwise stated)

11 Property, plant and equipment - Tangible assets

Owned Assets	Gross Block			Depreciation			Net Block March 31, 2020
	April 1, 2019	Additions	March 31, 2020	Disposal	For the year	March 31, 2020	
Leasehold improvements	-	4,373,829	4,373,829	-	416,230	416,230	3,957,599
Furniture and fixtures	-	533,680	533,680	-	39,511	39,511	494,169
Office equipment	-	1,336,686	1,336,686	-	164,607	164,607	1,172,079
Computer equipment	-	1,911,247	1,911,247	-	455,759	455,759	1,455,488
Total	-	8,155,442	8,155,442	-	1,076,107	1,076,107	7,079,335

Owned Assets	Gross Block			Depreciation			Net Block March 31, 2019
	April 1, 2018	Additions	March 31, 2019	Disposal	For the year	March 31, 2019	
Leasehold improvements	-	-	-	-	-	-	-
Furniture and fixtures	-	-	-	-	-	-	-
Office equipment	-	-	-	-	-	-	-
Computer equipment	-	-	-	-	-	-	-
Total	-	-	-	-	-	-	-



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS

(All amounts in Rs. unless otherwise stated)

	As at	
	March 31, 2020	March 31, 2019
12 Long-term loans and advances		
Unsecured, considered good:		
Balances with government authorities	5,847,996	-
Capital advances	725,038	-
Security deposits	8,110,250	3,000
	14,683,284	3,000
13 Trade receivables		
Unsecured, considered good:		
Outstanding for a period exceeding 6 months from the date they are due for payment	-	-
Others	3,633,619	-
	3,633,619	-
14 Cash and bank balances		
Cash and cash equivalents:		
Cash on hand	500	-
Bank balances:		
In current accounts	222,128,392	2,218,873
Demand deposits (original maturity less than 3 months)*	1,250,000	-
	223,378,892	2,218,873
*Held as lien by the bank against corporate credit card		
15 Short-term loans and advances		
Unsecured, considered good:		
Prepaid expenses	274,197	-
Advance to suppliers	755,647	-
Advances to employees	735,426	-
	1,765,270	-
16 Other current assets		
Interest accrued on fixed deposits	23,640	-
	23,640	-
17 Contingent liabilities	Nil	Nil
18 Capital and other commitments	985,888	-



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS

(All amounts in Rs. unless otherwise stated)

	Year ended March 31,2020	Year ended March 31,2019
19 Donations and Grants		
Donation (Unrestricted) (refer Note 27)	314,429,147	502,000
	314,429,147	502,000
20 Other income		
Interest income	23,640	-
	23,640	-
21 Employee benefits expense		
Salaries and bonus	28,428,130	-
Contribution to Provident and other funds (refer Note (a) below)	543,544	-
Gratuity (refer Note (b) below)	535,479	-
Staff welfare expenses	375,967	-
	29,883,120	-
Employee benefits:		
The disclosure as envisaged in AS 15 on Employee Benefits are as follows:		
(a) Defined contribution plan:		
Amount recognised in the Statement of Income and Expenditure:		
Provident fund paid to the authorities	506,716	-
Provident fund administration and other charges	36,828	-
	543,544	-
(b) Defined benefit plans		
The Company provides for gratuity, a defined benefit plan (the Gratuity Plan), to its employees. The Gratuity Plan provided a lump sum payment to vested employees at retirement or termination of employment, an amount based on the respective employee's last drawn salary and years of employment with the Company.		
	As at	
	March 31, 2020	March 31, 2019
(i) Present value of defined benefit obligation		
Balance at the beginning of the year	-	-
Current service cost	264,685	-
Interest cost	32,822	-
Actuarial loss	48,600	-
Benefits paid	-	-
Transfers	189,372	-
Balance at the end of the year	535,479	-
(ii) Fair value of Plan Assets		-
(iii) Assets and Liabilities recognised in the Balance Sheet		
Present value of defined benefit obligation	535,479	-
Less: Fair value of plan assets	-	-
Amount recognised as liability	535,479	-
Recognised under:		
Long-term provision (refer Note 7)	533,166	-
Short-term provision (refer Note 10)	2,313	-



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS

(All amounts in Rs. unless otherwise stated)

	As at	
	March 31, 2020	March 31, 2019
(iv) Expense recognised in Statement of Income and Expenditure		
Current service cost	264,685	-
Interest cost	32,822	-
Expected return on plan assets	-	-
Actuarial loss	48,600	-
Transfers	189,372	-
Total expense	535,479	-
(v) Major category of plan assets as a % of total plan assets	-	-
(vi) Principal actuarial assumptions		
Discount rate	6.60%	-
Expected salary increase	10.00%	-
Attrition rate	12.50%	-
Retirement age	60 Years	-
Mortality	India Assured Lives Mortality 2012- 14Ult	-
(vii) Amount recognised in current year and previous four years		

	2020	2019	2018	2017	2016
Defined benefit obligation	535,479	-	-	-	-
Plan assets	-	-	-	-	-
Deficit	535,479	-	-	-	-
Experience gain adjustment on plan liabilities	(4,588)	-	-	-	-

(viii) **Expected contribution to the funds next**

Nil as the Gratuity liability is unfunded.

Notes:

(i) The discount rate is based on the prevailing market yields of Indian government securities as at the Balance Sheet date for the estimated term of the obligation.

(ii) The estimates of future increase in compensation levels, considered in the actuarial valuation, have taken into account inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS

(All amounts in Rs. unless otherwise stated)

22 Other expenses

	Year ended March 31,2020	Year ended March 31,2019
Rent (refer Note 28)	10,703,596	-
Repair and maintainance	1,679,638	-
Information and Education Expense	2,789,860	-
Audit fees		
Statutory audit	500,000	44,250
Others	100,000	-
Commission charges	707,900	-
Insurance	448,419	-
IT support charges	1,395,617	-
Legal and professional fees	3,304,963	7,500
Seminar expense	3,062,871	-
Rates & Taxes	148,572	216,930
Membership fee	191,472	-
Registry fees	498,299	-
Travel expense	3,431,936	-
Net loss on foreign currency transactions and translations	4,097,943	-
Miscellaneous Expenses	2,238,484	3,266
	35,299,570	271,946



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS

(All amounts in Rs. unless otherwise stated)

		Year ended March 31,2020	Year ended March 31,2019
23 Expenditure in foreign currency:			-
Donor and transplantation expense - Testing charges		25,888,364	
Traveling expense		766,790	-
Others		2,108,131	
24 Earnings in foreign currency:			-
Fees from activities		4,909,685	
Donation (refer Note 27)		313,928,647	-
25 C.I.F value of imports			
Capital goods		Nil	Nil
26 Earnings per share *			
Nominal value of equity share (Rs.)		10	10
Surplus for the year	A	207,418,415	230,054
Weighted average number of shares outstanding	B	200,000	200,000
Basic (Rs.)	A/B	1,037	1

*Represents surplus per share, as the Company is registered under Section 8 of Companies Act, 2013.



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS

(All amounts in Rs. unless otherwise stated)

27 Related Party Disclosures

A. Names of related parties and nature of relationship:

Ref	Description of relationship	Names of related parties
a)	<i>Parties where control exists:</i>	
	Holding company	DKMS Gemeinnutzige GmbH, Germany
	Enterprises with significant influence	Bangalore Medical Services Trust
	Fellow Subsidiary	DKMS Life Science Lab, GmbH
b)	<i>Key Management Personnel:</i>	
	Directors	Dr. Latha Jagannathan * Prabhashankar K N * Vinod Swaroop Saxena * Alexander Heinrich Schmidt * Sirko Geist *
	Chief Executive Officer	Patrick Paul


* No transactions during the year.

B. Summary of transactions with related parties and balance outstanding at year end are as follows:

Nature of transaction	Holding company/ Fellow subsidiaries / Enterprise having significant influence [(a)(i)]	Key Management Personnel [b]	Total
Transactions during the year:			
i. Revenue from operations:			
Donations Received	313,928,647 (502,000)	- (-)	313,928,647 (502,000)
ii. Reimbursement of expenses to			
DKMS Gemeinnutzige GmbH, Germany	2,190,945 (-)	- (-)	2,190,945 (-)
DKMS Life Science Lab, GmbH	24,130,067 (-)	- (-)	24,130,067 (-)
Bangalore Medical Services Trust	1,407,450 (-)	- (-)	1,407,450 (-)
iii. Remuneration paid (refer Note 1 below)			
Patrick Paul	- (-)	11,298,266 (-)	11,298,266 (-)
iv. Contribution to Sharecapital			
DKMS Gemeinnutzige GmbH, Germany	- (1,425,000)	- (-)	- (1,425,000)
Bangalore Medical Services Trust	- (475,000)	- (-)	- (475,000)
Balances at the end of the year:			
Trade Payables			
DKMS Gemeinnutzige GmbH, Germany	2,683,672 (-)	- (-)	2,683,672 (-)
DKMS Life Science Lab, GmbH	25,891,396 (-)	- (-)	25,891,396 (-)
Bangalore Medical Services Trust	356,700 (-)	- (-)	356,700 (-)

Notes:

- Excludes provision for gratuity and compensated absences as these are provided in the books on the basis of actuarial valuation for the Company as a whole and hence individual figures cannot be identified and includes perquisites as per Income Tax Rules.
- Figures in brackets relate to previous year.



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS
(All amounts in Rs. unless otherwise stated)

28 Operating leases

The Company has entered into operating lease agreements for office premises. The leases for office premises are non-cancellable in nature for a period upto three years and includes both cancellable and non cancellable leases. Most of the leases are renewable for further periods on mutually agreeable terms and also include escalation clauses.

	Year ended March 31,2020	Year ended March 31,2019
Rent (including minimum lease payments)	10,703,596	-
Total future minimum lease payments under non-cancellable operating leases:		
- Not later than one year	8,494,800	-
- Later than one year and not later than five years	95,481,552	-

29 Dues to micro and small enterprises

The Company has certain dues to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act'). The disclosure pursuant to the said MSMED Act are as follows:

	Year ended March 31,2020	Year ended March 31,2019
(a) Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	51,840	-
(b) Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end	-	-
(c) Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	622,080	-
(d) Interest paid, other than under Section 16 for MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(e) Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(f) Interest due and payable towards suppliers registered under MSMED Act, for payments already made	-	-
(g) Further interest remaining due and payable for earlier years	-	-

The above information has been determined based on vendors identified by the Company on the basis of confirmations received from vendors.

30 Taxation

Current Tax

The Company is registered under Section 12A read with Section 12AA of the Income Tax Act, 1961 in India vide Commissioner of Income Tax's communication referred letter number CIT(E)BLR/12A/M-257/AAGCB4824Q/ITO(E)-1/Vol 2016-2017 dated May 03, 2016 and accordingly, is exempt from paying Income tax on excess of income over expenditure to the extent income is applied for Charitable or religious purpose in India and subject to compliance as stipulated in aforesaid approval letter. Therefore income tax is computed on activities incurred outside India. The company is also registered under Section 80G of the Income Tax Act, 1961.

Transfer pricing

The Finance Act 2001 has introduced with effect from assessment year 2002-2003 (April 1, 2001), detailed Transfer Pricing regulations for computing the taxable income and expenditure from 'international transactions' between associated enterprises on an 'arm's length' basis. These regulations, inter alia, also require the maintenance of prescribed documents and information including furnishing a report from an Accountant within the due date of filing the Return of Income.

For the year ended March 31, 2019, the Company did not have any taxable income and expenditure from 'international transactions' and thus had not undertaken a study under the regulations. For the year ended March 31, 2020, the Company will take necessary steps including conducting a study and also obtain the prescribed certificate of the Accountant as required by the regulations. In the opinion of the management, no adjustment is expected to arise based on Transfer Pricing study for the current year.



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

NOTES TO THE FINANCIAL STATEMENTS
(All amounts in Rs. unless otherwise stated)

- 31** The provision of the Employee State Insurance Act, 1948 are not applicable to the company for the year ended March 31, 2020 and accordingly there is no expense in this regard for the year ended March 31, 2020 (Previous period: Nil).

32 Segment reporting

Primary Segment: Business Segment

The Company has considered the business segment as the primary reporting segment on the basis that the risk and returns of the Company is primarily determined by the nature of services. The business segment has been identified on the basis of the nature of services, the risks and returns, internal organisation and management structure and the internal performance reporting systems.

During the current year, the Company has been engaged in only one segment which is "to help and support people suffering from blood cancer and other diseases in particular to those for which unrelated stem cell transplant is an appropriate treatment and to set up stem cell donor center in India". Hence primary segment reporting disclosure is not applicable for the current year.

Secondary Segment: Geographic Segment

The Company rendered services to donors and donees in India and outside India during the current year. Accordingly, secondary segment has been identified based on location of the donors and donees (India and Outside India). Segment wise reporting disclosures are given below:

	March 31, 2020			March 31, 2019		
	Within India	Outside India	Total	Within India	Outside India	Total
Segment income by location of donees	7,175,787	4,945,124	12,120,911	-	-	-
Carrying amount of segment assets	247,561,721	3,002,319	250,564,040	2,221,873	-	2,221,873
Cost to acquire tangible assets	8,155,442	-	8,155,442	-	-	-

33 Derivative instrument and unhedged foreign currency exposure

Unhedged foreign currency exposure

	March 31, 2020		March 31, 2019	
	Amount in foreign currency	Amount in Rs.	Amount in foreign currency	Amount in Rs.
Trade receivable - USD	39,826	3,002,319	-	-
Trade Payables - Euro	358,272	29,754,346	-	-



DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)
NOTES TO THE FINANCIAL STATEMENTS
(All amounts in Rs. unless otherwise stated)

34 Impact of Covid 19

The spread of COVID-19 has severely impacted businesses around the globe. In many countries, including India, there has been severe disruption to regular business operations due to lock-downs, disruptions in transportation, supply chain, travel bans, quarantines, social distancing and other emergency measures.

As the situation is constantly evolving, the Company has considered various sources of information available up to the date of approval of financial statements in assessing the impact of COVID-19 pandemic in the financial statements for the year ended March 31, 2020.

The Company is incorporated under section 8 of the Companies Act, 2013, with the primary objective to help and support people suffering from blood cancer and other diseases in particular to those for which unrelated stem cell transplant is an appropriate treatment and to set up stem cell donor center in India. Management is of the view that there is significant uncertainty in the business environment, which has resulted in disruption in the operations of the company. Based on current assessment, management is of the view that this situation is likely to continue for the next quarter.

The Company operates mainly on donations received from the parent company and other donors and does not rely on any borrowings or other sources of finance. In the view of the management, there is no major impact on the immediate liquidity position of the company based on sensitivity analysis and detailed cash flow assessment carried out for the next one year from the date on which the financial statements are approved. The Company is also adequately supported by its holding company.

As part of its review of the year-end balance sheet, the Company has made an assessment of recoverability and carrying values of its assets comprising Property, Plant and Equipment and Other assets and has concluded that no further adjustments are required to be made to the carrying values of such assets as at March 31, 2020.

In view of the above, the Company has taken into account all the possible impact of known events arising from COVID-19 pandemic in the preparation of these financial statements. However, the impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration. The Company will continue to closely monitor any material changes to future economic conditions.

35 Previous year figures have been reclassified, where necessary, to conform to the current year's presentation.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Madhayi Kalva
Partner
Membership Number: 213550

Place: Bengaluru
Date: September 10, 2020

For and on behalf of the Board of Directors



Dr. Latha Jagannathan
Director
DIN: 00176248

Place: Bengaluru
Date: September 10, 2020



Prabhaskar K N
Director
DIN: 01499577

Place: Bengaluru
Date: September 10, 2020



Price Waterhouse Chartered Accountants LLP

Independent auditor's report

To the Members of DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)

Report on the audit of the financial statements

Opinion

1. We have audited the accompanying financial statements of DKMS BMST Foundation India (formerly BMST Stem Cell Donor Registry Foundation India) ("the Company"), which comprise the balance sheet as at March 31, 2020, the statement of Income and expenditure and cash flow statement for the year then ended and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2020, its income and its cash flows for the year then ended.

Basis for opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

4. We draw your attention to Note 34 to the financial statements, which describes the management's assessment of the impact of the outbreak of Coronavirus (Covid-19) on the business operations of the Company. The management believes that no adjustments are required in the financial statements as it does not impact the current financial year, however, in view of the various preventive measures taken (such as complete lock-down restrictions by the Government of India, travel restrictions etc.) and highly uncertain economic environment, a definitive assessment of the impact on the subsequent periods is highly dependent upon circumstances as they evolve.

Our opinion is not modified in respect of this matter.

Other Information

5. The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.



Price Waterhouse Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road, Ulsoor
Bangalore - 560 008
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Members of DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)
Report on audit of the Financial Statements

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Responsibilities of management and those charged with governance for the financial statements

6. The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
7. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

8. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
9. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances; but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.



Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Members of DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)
Report on audit of the Financial Statements

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
-
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern
 - Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Other Matter

11. The financial statements of the Company for the year ended March 31, 2019, were audited by another firm of chartered accountants under the Act who, vide their report dated September 19, 2019, expressed an unmodified opinion on those financial statements.

Report on other legal and regulatory requirements

12. As required by Section 143(3) of the Act, we report that:
- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Income and Expenditure and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act.
 - (e) In the absence of written representation from Vinod Swaroop Saxena, a director of the Company, who has vacated the office subsequent to the year end, we are unable to comment if he is disqualified as on March 31, 2020 from being appointed as a director in terms of Section 164(2) of the Act. On the basis of written representations received from the other directors as on March 31, 2020, and taken on record by the Board of Directors, none of the other directors are disqualified as on March 31, 2020, from being appointed as a director in terms of Section 164(2) of the Act.
 - (f) Clause (i) of section 143(3) is not applicable pursuant to notification G.S.R 583(E) dated June 13, 2017.



Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT


To the Members of DKMS BMST Foundation India
(formerly BMST Stem Cell Donor Registry Foundation India)
Report on audit of the Financial Statements

(g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. The Company does not have any pending litigations which would impact its financial position;
- ii. The Company has long-term contracts as at March 31, 2020 for which there were no material foreseeable losses. The Company does not have derivative contracts as at March 31, 2020;
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended March 31, 2020; and
- iv. The reporting on disclosures relating to Specified Bank Notes is not applicable to the Company for the year ended March 31, 2020.

13. The provisions of Section 197 read with Schedule V to the Act are applicable only to public companies. Accordingly, reporting under Section 197(16) of the Act is not applicable to the Company.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Madhavi Kalva
Partner
Membership Number: 213550

UDIN : 20213550AAAACE8011

Place: Bengaluru
Date: September 10, 2020